ADX71149 for epilepsy

ADX71149 for the treatment of epilepsy.

Our partnered drug candidate, ADX71149 is a novel orally active mGlu2 PAM for the treatment of epilepsy. Our partner, Janssen Pharmaceuticals, Inc., or Janssen, a subsidiary of Johnson & Johnson is conducting a placebo- controlled Phase 2a proof of concept clinical trial of ADX71149 in epilepsy patients since June 2021, part 1 is completed and we expect to announce the recommendations of independent interim research committee in early quarter 2 2023. 

Under our agreement with Janssen, Janssen is responsible for financing the development and commercialization, if any, of ADX71149.